Currently, there are 69.43M common shares owned by the public and among those 58.04M shares have been available to trade.
The company’s stock has a 5-day price change of -0.95% and 44.53% over the past three months. AKRO shares are trading 16.49% year to date (YTD), with the 12-month market performance down to -45.28% lower. It has a 12-month low price of $11.25 and touched a high of $53.77 over the same period. AKRO has an average intraday trading volume of 752.94K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 6.94%, 7.89%, and 19.81% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Akero Therapeutics Inc (NASDAQ: AKRO) shares accounts for 95.49% of the company’s 69.43M shares outstanding.
It has a market capitalization of $1.89B and a beta (3y monthly) value of -0.26. The earnings-per-share (ttm) stands at -$3.41. Price movements for the stock have been influenced by the stock’s volatility, which stands at 4.29% over the week and 5.70% over the month.
Earnings per share for the fiscal year are expected to decrease by -25.16%, and -8.82% over the next financial year.
Looking at the support for the AKRO, a number of firms have released research notes about the stock. BofA Securities stated their Neutral rating for the stock in a research note on April 22, 2024, with the firm’s price target at $30. Cantor Fitzgerald coverage for the Akero Therapeutics Inc (AKRO) stock in a research note released on September 19, 2023 offered a Overweight rating with a price target of $69. UBS was of a view on August 28, 2023 that the stock is Buy, while Morgan Stanley gave the stock Overweight rating on January 27, 2023, issuing a price target of $40- $65. Evercore ISI on their part issued Outperform rating on September 14, 2022.
